The FDA has approved Swiss pharmaceutical company Roche’s first companion diagnostic for identifying those patients with HER2 low-metastatic breast cancer who are eligible for ENHERTU.
Roche said regulatory review of this drug is ongoing in additional markets. FDA approval of the MS drug, Ocrevus Zunovo, came the day after the cancer drug approval. Like infused Ocrevus ...
Last year, the FDA approved Eli Lilly’s CDK4/6 inhibitor, abemaciclib or Verzenio, for use in stage 2 and 3 HR positive, HER2 negative breast cancer, but not for breast cancers that had not yet ...
Tumor-Induced B Cell Changes Reveal Potential Biomarker for Treatment Response in Triple Negative Breast Cancer ... 2024 — A review examines the prevailing theory of cancer evolution.
Like regular mammograms, this exam can be used for screening — the regular tests you get ... from breast cancer remains under study. While 3D mammogram machines are approved by the FDA ...
The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...
Mindpeak announces its collaboration with Roche that will integrate ... clinicans improve patient care and expanding personalized medicine. In a healthcare landscape where millions of diagnostic ...
Swiss pharmaceutical company Roche is contemplating divesting cancer data specialist Flatiron ... strong demand for newer drugs such as its eye medicine Vabysmo. (With inputs from Reuters) ...
Get it checked by a doctor, but don't panic. Chances are, your breast cancer isn't caused by a faulty gene. But in about 5% to 10% of cases, the cause is hereditary. Some lifestyle factors may ...
A pharmaceutical company, Roche, has partnered with OncoPadi, a digital healthcare services provider, to tackle breast cancer in Nigeria. According to a statement, Roche’s partnership with ...
Lunit's AI-powered biomarker, Lunit SCOPE PD-L1 TPS, integrates into Roche's navify ® Digital Pathology platform to enhance precision medicine ... for each cancer patient. Our FDA-cleared Lunit ...
These AI tools are designed to enhance pathology insights, helping benefit cancer patients through precision medicine and enabling ... risk profiling of invasive breast cancer. With these new ...